The frequency of FANCG GPV carriers in BC was insignificantly higher among patients who were not indicated for germline genetic testing than among those who were indicated [10/3451 (0.29%) vs. 10/6753 (0.15%); p = 0.19]. This evidence concerns the gene FANCG and breast cancer.